CSIMarket Company Name, Ticker, Industry, else..
 
Essa Pharma inc   (EPIX)
Other Ticker:  
 
 
Price: $6.0200 $-0.21 -3.371%
Day's High: $6.41 Week Perf: 3.97 %
Day's Low: $ 5.90 30 Day Perf: -12.12 %
Volume (M): 54 52 Wk High: $ 11.67
Volume (M$): $ 323 52 Wk Avg: $6.46
Open: $6.29 52 Wk Low: $2.85



 Market Capitalization (Millions $) 267
 Shares Outstanding (Millions) 44
 Employees 18
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -28
 Cash Flow (TTM) (Millions $) 48
 Capital Exp. (TTM) (Millions $) 0

Essa Pharma Inc
Essa Pharma Inc. is a clinical-stage biopharmaceutical company that focuses on developing novel therapies for the treatment of cancer. The company is headquartered in Vancouver, British Columbia, Canada, and was formed in 2009.

Essa Pharma primarily focuses on developing therapies that inhibit the androgen receptor and associated pathways, which are known to play a significant role in the development and progression of castration-resistant prostate cancer (CRPC). Their lead product candidate, EPI-7386, is currently under clinical investigation for the treatment of metastatic CRPC.

Essa Pharma has also developed a proprietary platform technology, called AP-01, which enables the identification of small molecules that are specific to oncogenic proteins, which could be developed into cancer therapeutics.

The company has partnerships and collaborations with different organizations to accelerate the development of their products. For instance, the company has a partnership with the University of California Los Angeles (UCLA) to investigate the use of their product, EPI-7386, in clinical trials for the treatment of advanced prostate cancer.

Overall, Essa Pharma is a clinical-stage biopharmaceutical company that is working towards developing innovative therapies for the treatment of cancer. The company has a strong pipeline of products and collaborations with leading academic institutions, which makes them a promising player in the biopharmaceutical industry.


   Company Address: Suite 720 Vancouver 0 BC
   Company Phone Number: 331-0962   Stock Exchange / Ticker: NASDAQ EPIX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Essa Pharma Inc

Investors and analysts concerned about Essa Pharma Inc's widening deficit and lack of revenue disclosure

The Major Pharmaceutical Preparations industry has recently come under fire as company figures continue to reveal concerning trends. The latest reports from the second quarter of 2024 show that operating profit for Essa Pharma Inc has increased to $10.493489 million, a significant improvement compared to the same period in 2023. However, the company has failed to disclose any revenue numbers, leaving investors and industry analysts questioning the overall health of the company.
One of the most alarming revelations from the latest reports is the widening deficit, which has ballooned to $-8.990 million. This significant loss highlights the challenges that Essa Pharma Inc is facing in terms of monetizing its products and generating sufficient revenue to cover its expenses. Despite the increase in operating earnings, which rose by 27.76%, the company's overall financial picture remains bleak.
Essa Pharma Inc

Essa Pharma Inc Shines with Impressive $7.59 Million Operating Profit in Q1 2024

The Major Pharmaceutical Preparations industry is an ever-evolving sector that constantly presents opportunities for growth and success. While the bellwether companies in this field have long been the focus of investors, it is important not to overlook the potential of smaller corporations like EPIX and Essa Pharma Inc.
The recent operating profit reported by EPIX of $7.594632 million for the first quarter of 2024 is certainly impressive. This shows that the company is on the right track towards profitability and success. Additionally, Essa Pharma Inc has also shown promising signs of improvement, with operating profit increasing from $7.865719 million in the first quarter of 2022 to -$5.964 million in the first quarter of 2024.
Essa Pharma Inc

Essa Pharma Inc Remains Steadfast Amidst the Third Quarter of 2023, Reflecting Comparable Performance to Previous Year

Essa Pharma Inc, a biopharmaceutical company, has experienced a steady increase in its shares over the past five days, resulting in a year-to-date performance of 12.89%. Currently trading on NASDAQ, the company's shares are 1.8% higher than its 52-week average.
In terms of financial performance, for the period spanning April to June 2023, Essa Pharma Inc saw a decrease in its losses per share compared to the same period last year. The company reported a loss of $-0.17 per share, compared to $-0.20 a year ago. Additionally, there was a slight increase in the loss from the prior reporting season, with a loss of $-0.16 per share. However, it is important to note that the company's revenue remained unchanged at $0.00 million, both from the same period last year and sequentially.
Essa Pharma Inc

Essa Pharma Inc's Financial Improvements: Losses Reduced to $-0.16 per Share in Q2 2023, Promising Growth Ahead

Essa Pharma Inc Shows Promising Signs of Improvement
Despite reporting a loss in the financial second quarter of 2023, Essa Pharma Inc has shown significant progress compared to the previous year. The company's losses decreased from $-0.25 per share to $-0.16 per share, indicating a positive trend. Additionally, the revenue remained stable at $0.00 million, suggesting that the company has been able to maintain its sales performance.
One of the most encouraging aspects of Essa Pharma Inc's financial results is the significant reduction in net loss. The company reported a net loss of $-7.060 million, which is a notable improvement from the $-10.855 million loss recorded in the same quarter a year ago. This reduction in losses demonstrates that Essa Pharma Inc is taking effective measures to control its expenses and improve its financial position.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com